{
    "info": {
        "nct_id": "NCT03854110",
        "official_title": "Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GP-2250 With Gemcitabine in Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Following Progression on 5-FU-based Chemotherapy",
        "inclusion_criteria": "Informed Consent:\n\n1. Capable of giving signed informed consent as described in Appendix 1: Regulatory, Ethical, and Trial Oversight Considerations which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n2. Male and female subjects age > 18 years at the time of trial entry. Type of Subject and Disease Characteristics\n3. Histologically or cytologically confirmed advanced unresectable or metastatic pancreatic adenocarcinoma\n4. Subjects should be eligible to receive gemcitabine monotherapy for the treatment of their pancreatic cancer per the judgment of the Investigator\n5. Subjects must have documented disease progression while receiving or within 3 months of completing prior treatment with 5-fluorouracil-based chemotherapy.\n6. Subjects must have at least one RECIST Version 1.1 defined measurable tumor lesion\n7. Subjects must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1.\n8. Subjects with known central nervous system metastasis must have undergone brain targeted treatment and must be asymptomatic or radiographically and clinically stable (including not requiring steroids or anti-seizure medications) for at least 4 weeks prior to enrollment.\n9. All subjects must consent to provide archived tumor specimens for biomarker studies.\n10. Subjects must have adequate organ function as indicated by the following laboratory values:\n\n    1. Absolute neutrophil count (ANC) ≥ 1,500 /mL\n    2. Platelets ≥ 100,000 / mL\n    3. Hemoglobin ≥ 9 g/dL\n    4. Serum creatinine ≤ 1.5 X upper limit of normal (ULN)\n    5. Serum total bilirubin ≤ 1.5 × ULN\n    6. Aspartate aminotransferase (AST), (Serum glutamic oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT), and (Serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 × ULN OR ≤ 5 × ULN for subjects with liver metastasis\n    7. International Normalized Ratio (INR) and/or Prothrombin Time (PT) ≤ 1.5 × ULN\n    8. Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN\n    9. Serum Albumin ≥ 3 gm/dL\n11. Female subjects of childbearing potential (woman of childbearing potential [WOCBP]) must have a negative serum pregnancy test.\n12. Subjects must use adequate contraception for the duration of the trial:\n\n    1. Male subjects must agree to use a highly effective contraception during the treatment period and for at least 3 months after the last dose of trial intervention and refrain from donating sperm during this period\n    2. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a WOCBP OR a WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 3 months after the last dose of trial intervention.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Diagnosis of any active malignancy other than pancreatic cancer within the past 2 years (not including non-melanoma skin carcinoma, ductal carcinoma in situ of the breast, or carcinoma in situ of uterine cervix treated with curative intent).\n2. Subjects has a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonia or multiple allergies, clinically significant cardiovascular disease such as unstable angina, myocardial infarction, or acute coronary syndrome with <=6 months prior to the start of study treatment, symptomatic or uncontrolled arrhythmia, congestive heart failure, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or ascites requiring paracentesis in the 4 weeks prior to Screening.\n3. Any other medical, psychiatric, or social condition deemed by the Investigator to be likely to interfere with a subject's rights, safety, welfare, or ability to sign informed consent, cooperate and participate in the trial, or which would interfere with the interpretation of the results.\n4. Subject has undergone major surgery, other than diagnostic surgery (ie, surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study.\n5. Prior history or current signs of hyphema or glaucoma.\n6. History of sickle cell disease or hereditary non-spherocytic hemolytic anemia.\n7. Baseline QTc interval >480 msec for female subjects or >450 msec for male subjects.\n8. Subject is unwilling or unable to comply with study procedures or is planning to take a vacation for 7 or more consecutive days during the source of the study.\n9. First degree relative of the investigator, study staff or the sponsor.\n10. Positive test for SARS-CoV2 (COVID-19) by polymerase chain reaction (PCR) testing within one week prior to Screening.\n11. Any chemotherapy administered within 3 weeks or 5 half-lives (whichever is shorter) before first dose of GP-2250; other anti-cancer therapy (including surgery, radiotherapy, immunotherapy, hormone therapy, or targeted therapy) administered within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of GP-2250; or within 6 weeks in the case of certain therapies (mitomycin C and nitrosoureas).\n\n    Prior/Concurrent Clinical Trial Experience:\n12. Investigational therapy administered within 4 weeks or 5-half lives (whichever is shorter) before the first dose of GP-2250.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "5. Subjects must have documented disease progression while receiving or within 3 months of completing prior treatment with 5-fluorouracil-based chemotherapy.",
            "criterions": [
                {
                    "exact_snippets": "documented disease progression while receiving or within 3 months of completing prior treatment with 5-fluorouracil-based chemotherapy",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to 5-fluorouracil-based chemotherapy",
                            "expected_value": [
                                "while receiving",
                                "within 3 months of completing"
                            ]
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. International Normalized Ratio (INR) and/or Prothrombin Time (PT) ≤ 1.5 × ULN",
            "criterions": [
                {
                    "exact_snippets": "International Normalized Ratio (INR) ... ≤ 1.5 × ULN",
                    "criterion": "International Normalized Ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Prothrombin Time (PT) ≤ 1.5 × ULN",
                    "criterion": "Prothrombin Time (PT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Subjects with known central nervous system metastasis must have undergone brain targeted treatment and must be asymptomatic or radiographically and clinically stable (including not requiring steroids or anti-seizure medications) for at least 4 weeks prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Subjects with known central nervous system metastasis",
                    "criterion": "central nervous system metastasis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have undergone brain targeted treatment",
                    "criterion": "brain targeted treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must be asymptomatic",
                    "criterion": "symptoms of CNS metastasis",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "asymptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "radiographically and clinically stable",
                    "criterion": "CNS metastasis stability",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "radiographically and clinically stable"
                        }
                    ]
                },
                {
                    "exact_snippets": "not requiring steroids or anti-seizure medications",
                    "criterion": "requirement for steroids or anti-seizure medications",
                    "requirements": [
                        {
                            "requirement_type": "medication requirement",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "for at least 4 weeks prior to enrollment",
                    "criterion": "duration of stability",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Subjects should be eligible to receive gemcitabine monotherapy for the treatment of their pancreatic cancer per the judgment of the Investigator",
            "criterions": [
                {
                    "exact_snippets": "eligible to receive gemcitabine monotherapy for the treatment of their pancreatic cancer",
                    "criterion": "eligibility for gemcitabine monotherapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "per the judgment of the Investigator",
                    "criterion": "Investigator judgment",
                    "requirements": [
                        {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. All subjects must consent to provide archived tumor specimens for biomarker studies.",
            "criterions": [
                {
                    "exact_snippets": "All subjects must consent to provide archived tumor specimens",
                    "criterion": "consent to provide archived tumor specimens",
                    "requirements": [
                        {
                            "requirement_type": "consent",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "archived tumor specimens for biomarker studies",
                    "criterion": "archived tumor specimens",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Informed Consent:",
            "criterions": [
                {
                    "exact_snippets": "Informed Consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "obtained",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Female subjects of childbearing potential (woman of childbearing potential [WOCBP]) must have a negative serum pregnancy test.",
            "criterions": [
                {
                    "exact_snippets": "Female subjects of childbearing potential (woman of childbearing potential [WOCBP])",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative serum pregnancy test",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Subjects must use adequate contraception for the duration of the trial:",
            "criterions": [
                {
                    "exact_snippets": "Subjects must use adequate contraception for the duration of the trial",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "adequacy",
                            "expected_value": "adequate"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "for the duration of the trial"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Hemoglobin ≥ 9 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥ 9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Serum Albumin ≥ 3 gm/dL",
            "criterions": [
                {
                    "exact_snippets": "Serum Albumin ≥ 3 gm/dL",
                    "criterion": "serum albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "gm/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Subjects must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a WOCBP OR a WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 3 months after the last dose of trial intervention.",
            "criterions": [
                {
                    "exact_snippets": "female subject",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "not pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "not breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Not a WOCBP",
                    "criterion": "women of childbearing potential (WOCBP) status",
                    "requirements": [
                        {
                            "requirement_type": "WOCBP",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "a WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 3 months after the last dose of trial intervention",
                    "criterion": "contraceptive use agreement (for WOCBP)",
                    "requirements": [
                        {
                            "requirement_type": "contraceptive guidance agreement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Male subjects must agree to use a highly effective contraception during the treatment period and for at least 3 months after the last dose of trial intervention and refrain from donating sperm during this period",
            "criterions": [
                {
                    "exact_snippets": "Male subjects must agree to use a highly effective contraception during the treatment period and for at least 3 months after the last dose of trial intervention",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the treatment period and for at least 3 months after the last dose of trial intervention"
                        }
                    ]
                },
                {
                    "exact_snippets": "refrain from donating sperm during this period",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "refrain from",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during this period"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Capable of giving signed informed consent as described in Appendix 1: Regulatory, Ethical, and Trial Oversight Considerations which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.",
            "criterions": [
                {
                    "exact_snippets": "Capable of giving signed informed consent",
                    "criterion": "informed consent capability",
                    "requirements": [
                        {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol",
                    "criterion": "protocol and ICF compliance",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Aspartate aminotransferase (AST), (Serum glutamic oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT), and (Serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 × ULN OR ≤ 5 × ULN for subjects with liver metastasis",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST), (Serum glutamic oxaloacetic transaminase [SGOT]) ... ≤ 2.5 × ULN OR ≤ 5 × ULN for subjects with liver metastasis",
                    "criterion": "aspartate aminotransferase (AST) / serum glutamic oxaloacetic transaminase (SGOT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (for subjects with liver metastasis)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT), and (Serum glutamic pyruvic transaminase [SGPT]) ... ≤ 2.5 × ULN OR ≤ 5 × ULN for subjects with liver metastasis",
                    "criterion": "alanine aminotransferase (ALT) / serum glutamic pyruvic transaminase (SGPT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (for subjects with liver metastasis)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Male and female subjects age > 18 years at the time of trial entry. Type of Subject and Disease Characteristics",
            "criterions": [
                {
                    "exact_snippets": "Male and female subjects",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "age > 18 years at the time of trial entry",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Absolute neutrophil count (ANC) ≥ 1,500 /mL",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1,500 /mL",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "/mL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Subjects must have adequate organ function as indicated by the following laboratory values:",
            "criterions": [
                {
                    "exact_snippets": "adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Serum total bilirubin ≤ 1.5 × ULN",
            "criterions": [
                {
                    "exact_snippets": "Serum total bilirubin ≤ 1.5 × ULN",
                    "criterion": "serum total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Serum creatinine ≤ 1.5 X upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine ≤ 1.5 X upper limit of normal (ULN)",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Subjects must have at least one RECIST Version 1.1 defined measurable tumor lesion",
            "criterions": [
                {
                    "exact_snippets": "at least one RECIST Version 1.1 defined measurable tumor lesion",
                    "criterion": "RECIST Version 1.1 defined measurable tumor lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN",
            "criterions": [
                {
                    "exact_snippets": "Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN",
                    "criterion": "Activated Partial Thromboplastin Time (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Platelets ≥ 100,000 / mL",
            "criterions": [
                {
                    "exact_snippets": "Platelets ≥ 100,000 / mL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/ mL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Histologically or cytologically confirmed advanced unresectable or metastatic pancreatic adenocarcinoma",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed",
                    "criterion": "pancreatic adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "advanced unresectable or metastatic pancreatic adenocarcinoma",
                    "criterion": "pancreatic adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "disease stage",
                            "expected_value": [
                                "advanced unresectable",
                                "metastatic"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "9. First degree relative of the investigator, study staff or the sponsor.",
            "criterions": [
                {
                    "exact_snippets": "First degree relative of the investigator",
                    "criterion": "relationship to investigator",
                    "requirements": [
                        {
                            "requirement_type": "degree of relationship",
                            "expected_value": "first degree"
                        }
                    ]
                },
                {
                    "exact_snippets": "First degree relative of ... study staff",
                    "criterion": "relationship to study staff",
                    "requirements": [
                        {
                            "requirement_type": "degree of relationship",
                            "expected_value": "first degree"
                        }
                    ]
                },
                {
                    "exact_snippets": "First degree relative of ... the sponsor",
                    "criterion": "relationship to sponsor",
                    "requirements": [
                        {
                            "requirement_type": "degree of relationship",
                            "expected_value": "first degree"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Diagnosis of any active malignancy other than pancreatic cancer within the past 2 years (not including non-melanoma skin carcinoma, ductal carcinoma in situ of the breast, or carcinoma in situ of uterine cervix treated with curative intent).",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of any active malignancy other than pancreatic cancer within the past 2 years",
                    "criterion": "active malignancy (other than pancreatic cancer)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "cancer type exclusion",
                            "expected_value": [
                                "pancreatic cancer"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Prior/Concurrent Clinical Trial Experience:",
            "criterions": [
                {
                    "exact_snippets": "Prior/Concurrent Clinical Trial Experience",
                    "criterion": "clinical trial experience",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": "prior or concurrent participation in a clinical trial"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. History of sickle cell disease or hereditary non-spherocytic hemolytic anemia.",
            "criterions": [
                {
                    "exact_snippets": "History of sickle cell disease",
                    "criterion": "sickle cell disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hereditary non-spherocytic hemolytic anemia",
                    "criterion": "hereditary non-spherocytic hemolytic anemia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Investigational therapy administered within 4 weeks or 5-half lives (whichever is shorter) before the first dose of GP-2250.",
            "criterions": [
                {
                    "exact_snippets": "Investigational therapy administered within 4 weeks or 5-half lives (whichever is shorter) before the first dose of GP-2250.",
                    "criterion": "investigational therapy administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration before first dose of GP-2250",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Subject has undergone major surgery, other than diagnostic surgery (ie, surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study.",
            "criterions": [
                {
                    "exact_snippets": "Subject has undergone major surgery, other than diagnostic surgery (ie, surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": "other than diagnostic surgery (ie, surgery done to obtain a biopsy for diagnosis without removal of an organ)"
                        },
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to Day 1 of treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Any other medical, psychiatric, or social condition deemed by the Investigator to be likely to interfere with a subject's rights, safety, welfare, or ability to sign informed consent, cooperate and participate in the trial, or which would interfere with the interpretation of the results.",
            "criterions": [
                {
                    "exact_snippets": "Any other medical, psychiatric, or social condition deemed by the Investigator to be likely to interfere with a subject's rights, safety, welfare, or ability to sign informed consent, cooperate and participate in the trial, or which would interfere with the interpretation of the results.",
                    "criterion": "medical, psychiatric, or social condition",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with rights, safety, welfare, ability to sign informed consent, cooperate and participate in the trial, or interpretation of results",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Baseline QTc interval >480 msec for female subjects or >450 msec for male subjects.",
            "criterions": [
                {
                    "exact_snippets": "Baseline QTc interval >480 msec for female subjects",
                    "criterion": "QTc interval",
                    "requirements": [
                        {
                            "requirement_type": "baseline value",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "msec"
                            }
                        },
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "Baseline QTc interval ... >450 msec for male subjects",
                    "criterion": "QTc interval",
                    "requirements": [
                        {
                            "requirement_type": "baseline value",
                            "expected_value": {
                                "operator": ">",
                                "value": 450,
                                "unit": "msec"
                            }
                        },
                        {
                            "requirement_type": "sex",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Positive test for SARS-CoV2 (COVID-19) by polymerase chain reaction (PCR) testing within one week prior to Screening.",
            "criterions": [
                {
                    "exact_snippets": "Positive test for SARS-CoV2 (COVID-19) by polymerase chain reaction (PCR) testing",
                    "criterion": "SARS-CoV2 (COVID-19) infection by PCR",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "within one week prior to Screening",
                    "criterion": "time since positive SARS-CoV2 PCR test",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Subjects has a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonia or multiple allergies, clinically significant cardiovascular disease such as unstable angina, myocardial infarction, or acute coronary syndrome with <=6 months prior to the start of study treatment, symptomatic or uncontrolled arrhythmia, congestive heart failure, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or ascites requiring paracentesis in the 4 weeks prior to Screening.",
            "criterions": [
                {
                    "exact_snippets": "history of interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of slowly progressive dyspnea and unproductive cough",
                    "criterion": "slowly progressive dyspnea and unproductive cough",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "sarcoidosis",
                    "criterion": "sarcoidosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "silicosis",
                    "criterion": "silicosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "idiopathic pulmonary fibrosis",
                    "criterion": "idiopathic pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pulmonary hypersensitivity pneumonia",
                    "criterion": "pulmonary hypersensitivity pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "multiple allergies",
                    "criterion": "multiple allergies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant cardiovascular disease such as unstable angina, myocardial infarction, or acute coronary syndrome with <=6 months prior to the start of study treatment",
                    "criterion": "clinically significant cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "subtypes",
                            "expected_value": [
                                "unstable angina",
                                "myocardial infarction",
                                "acute coronary syndrome"
                            ]
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic or uncontrolled arrhythmia",
                    "criterion": "arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification",
                    "criterion": "cardiac disease (NYHA Class 3 or 4)",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": [
                                "Class 3",
                                "Class 4"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "ascites requiring paracentesis in the 4 weeks prior to Screening",
                    "criterion": "ascites requiring paracentesis",
                    "requirements": [
                        {
                            "requirement_type": "time since paracentesis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Subject is unwilling or unable to comply with study procedures or is planning to take a vacation for 7 or more consecutive days during the source of the study.",
            "criterions": [
                {
                    "exact_snippets": "Subject is unwilling or unable to comply with study procedures",
                    "criterion": "compliance with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "planning to take a vacation for 7 or more consecutive days during the source of the study",
                    "criterion": "vacation during study",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "consecutiveness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Any chemotherapy administered within 3 weeks or 5 half-lives (whichever is shorter) before first dose of GP-2250; other anti-cancer therapy (including surgery, radiotherapy, immunotherapy, hormone therapy, or targeted therapy) administered within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of GP-2250; or within 6 weeks in the case of certain therapies (mitomycin C and nitrosoureas).",
            "criterions": [
                {
                    "exact_snippets": "Any chemotherapy administered within 3 weeks or 5 half-lives (whichever is shorter) before first dose of GP-2250",
                    "criterion": "chemotherapy administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "other anti-cancer therapy (including surgery, radiotherapy, immunotherapy, hormone therapy, or targeted therapy) administered within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of GP-2250",
                    "criterion": "other anti-cancer therapy administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "within 6 weeks in the case of certain therapies (mitomycin C and nitrosoureas)",
                    "criterion": "mitomycin C or nitrosoureas administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "5. Prior history or current signs of hyphema or glaucoma.",
            "criterions": [
                {
                    "exact_snippets": "Prior history ... of hyphema",
                    "criterion": "hyphema",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "current signs of hyphema",
                    "criterion": "hyphema",
                    "requirements": [
                        {
                            "requirement_type": "current signs",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior history ... of glaucoma",
                    "criterion": "glaucoma",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "current signs of glaucoma",
                    "criterion": "glaucoma",
                    "requirements": [
                        {
                            "requirement_type": "current signs",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}